REG - Eco Animal Health Gp - Deferred Share Option Award to Executive Directors

ECO Animal HealthAnnouncement

29/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240829:nRSc0512Ca&default-theme=true

RNS Number : 0512C  Eco Animal Health Group PLC  29 August 2024

29 August 2024

ECO Animal Health Group plc

("ECO" or the "Company")

 

Deferred Share Option Awards to Executive Directors

 

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health
company with a portfolio of marketed veterinary products and a maturing
proprietary R&D pipeline, announces that on 28 August 2024 nominal cost
share options were granted under the Company's Deferred Bonus Plan ("DBS")
over 143,452 ordinary shares in the Company (representing approximately 0.21
percent of the Company's issued share capital) to two Executive Directors
listed below. These awards relate to the deferral of 33% of the annual bonus
for Executive Directors earned in respect of the Company's financial year
ended 31 March 2024.

 

 Name          Position                 Number of Deferred Share Options
 David Hallas  Chief Executive Officer  82,437
 Chris Wilks   Chief Financial Officer  61,015

 

As indicated in the Circular to shareholders dated 4 February 2021, the DBS
has been established to allow the Remuneration Committee to require a
significant part of the annual bonuses paid to Executive Directors to be
deferred in exchange for an award of nominal cost options which vest after 3
years.

 

-Ends-

For further information please contact:

 

 ECO Animal Health Group plc                                    020 8447 8899

 David Hallas (CEO)

 Christopher Wilks (CFO)
 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Phil Davies

 Sam Butcher
 Investec (Joint Broker)                                        020 7597 5970

 Gary Clarence

 Lydia Zychowska
 Equity Development                                             020 7065 2692

 Hannah Crowe

 Matt Evans
 ICR Consilium (Financial PR)                                   020 3709 5700

 Mary-Jane Elliott                                              ecoanimalhealth@consilium-comms.com

 Jessica Hodgson

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.

 

Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.

 

Our lead product, Aivlosin® is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.

Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com)

 

 

 

PDMR Notification - ECO DBS Deferred Share Option Awards

 1.                          Details of the person discharging managerial responsibilities / person closely
                             associated
 a.                          Name                                       1.    David Hallas

                                                                        2.    Chris Wilks

 2.                          Reason for the notification
 a.                          Position/status                            1.    Chief Executive Officer

                                                                        2.    Chief Financial Officer

 b.                          Initial notification                       Initial notification

                             /Amendment
 3.                          Details of the issuer, emission allowance market participant, auction
                             platform, auctioneer or auction monitor
 a.                          Name                                       Eco Animal Health Group Plc
 b.                          LEI                                        2138009XN9DJ3YP70B55
 4.                          Details of the transaction(s): section to be repeated for (i) each type of
                             instrument; (ii) each type of transaction; (iii) each date; and (iv) each
                             place where transactions have been conducted
 a.                          Description of the                         Options over ordinary shares of 5p each.

                             Financial instrument, type of instrument

                             Identification code                        GB0032036807

 b.                          Nature of the transaction                  Award of nominal cost share options under the Company's DBS.
 c.                          Price(s) and volume(s)                     Numbers 1 and 2 in the left-hand column correspond to the relevant PDMR as
                                                                        detailed in boxes 1a and 2a above.

Price(s)      Volume(s)

                                                                        1.    5p      82,437
                                                                        2.    5p      61,015

 
 d.                          Aggregated information

                             Aggregated volume

                             Price                                      n/a

 e.                          Date of the transaction                    28 August 2024
 f.                          Place of the transaction                   Outside a trading venue.

 

d.

Aggregated information

Aggregated volume

Price

 

 

 

n/a

 

e.

Date of the transaction

28 August 2024

f.

Place of the transaction

Outside a trading venue.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHPPMFTMTMTBJI